Lv51
818 积分 2024-06-11 加入
Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
2天前
已完结
Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
2天前
已完结
Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib
7天前
已完结
Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers
18天前
已完结
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
2个月前
已完结
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
2个月前
已完结
Coinhibition of the MEK/RTK pathway has high therapeutic efficacy in KRAS-mutant non-small cell lung cancer
2个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
2个月前
已完结
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer
2个月前
已完结
Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation–Positive Non–Small Cell Lung Cancer
2个月前
已完结
皖公网安备34019202002308
